Latest stories on TARS
Tarsus Pharmaceuticals reinstated with an Overweight at Barclays
The Fly63 · neutralanalyst
Tarsus Pharmaceuticals, Inc. (TARS) files 8-K
SEC 8-K50 · neutralgeneral
Jefferies raises Tarsus Pharmaceuticals price target on guidance
Investing.com Analyst Ratings61 · neutralanalyst
Tarsus Pharmaceuticals price target raised to $105 from $88 at Jefferies
The Fly67 · bullishanalyst
Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care
GlobeNewswire62 · neutralm&a
Tarsus to Participate in Upcoming Investor Conferences
Business Insider56 · neutralgeneral
Tarsus to Participate in Upcoming Investor Conferences
GlobeNewswire56 · neutralgeneral
Tarsus acquisition of Alkeus granted FTC early termination
Seeking Alpha67 · bullishm&a
Tarsus Pharmaceuticals price target raised to $100 from $97 at Oppenheimer
The Fly63 · neutralanalyst
Tarsus (TARS) Q2 2026 Earnings Call Transcript
The Motley Fool67 · bullishearnings
Tarsus projects $685M-$705M in 2026 XDEMVY net product sales while advancing Alkeus acquisition
Seeking Alpha73 · bullishproduct/pr
Tarsus Pharmaceuticals, Inc. (TARS) Q2 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
Tarsus Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation
Seeking Alpha50 · neutralearnings
Tarsus to acquire Alkeus Pharmaceuticals for $450M upfront, up to $800M total
The Fly63 · neutralm&a
Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition
Reuters63 · neutralm&a
Tarsus Pharmaceuticals to buy Alkeus Pharmaceuticals
Seeking Alpha63 · neutralm&a
Tarsus Pharmaceuticals Raises $125M in PIPE Financing
TipRanks24 · bearishgeneral
Tarsus Pharmaceuticals, Inc. GAAP EPS of -$0.43, revenue of $173.9M
Seeking Alpha48 · neutralearnings
Tarsus Pharmaceuticals, Inc. (TARS) files 8-K
SEC 8-K50 · neutralgeneral
Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth
StockTitan67 · bullishearnings
Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing
StockTitan24 · bearishgeneral
Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position
StockTitan63 · neutralm&a
Tarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
StockTitan50 · neutralgeneral
Tarsus Pharmaceuticals: Q2 2026 Rebound In Sales Possible, Catalysts Approaching
Seeking Alpha58 · neutralgeneral
Guggenheim cuts Tarsus Pharmaceuticals stock price target to $89
Investing.com Analyst Ratings34 · bearishanalyst